Role of chymase-dependent angiotensin II formation in monocrotaline-induced pulmonary hypertensive rats. 2006

Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
Department of Pharmacology, Osaka Medical College, Takatsuki City, Japan .

Angiotensin II-forming chymase is expressed in the pulmonary arteries of the monocrotaline-induced pulmonary hypertensive rats, but its actual role is unclear. We studied chymase-dependent angiotensin II formation in the pulmonary arteries of the monocrotaline-induced pulmonary hypertensive rats and observed the effects of an angiotensin II receptor blocker on vascular remodeling. Four weeks after the administration of monocrotaline (60 mg/kg, s.q.), echocardiographic, hemodynamic, morphometric and biochemical analyses were performed. Age-matched rats were used as controls. To evaluate the effects of an angiotensin II receptor blocker, 2 wk after beginning of monocrotaline treatment, the rats were given candesartan (10 mg/kg per day) or placebo for 2 wk. In the monocrotaline-induced pulmonary hypertensive rats, the elevated systolic pulmonary arterial pressure and right ventricular hypertrophy were observed. Medial hypertrophy of lung arterioles was also observed. Chymase activity and angiotensin II concentration, but not angiotensin-converting enzyme activity, were significantly increased in the lung. In the angiotensin II receptor blocker-treated group, both systolic pulmonary arterial pressure and right ventricular hypertrophy were significantly reduced, and arteriolar hypertrophy was also prevented. Thus, angiotensin II-forming chymase may play a role in the proliferation of the medial layer in the lung arterioles of monocrotaline-induced pulmonary hypertensive rats.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008297 Male Males
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001562 Benzimidazoles Compounds with a BENZENE fused to IMIDAZOLES.
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl

Related Publications

Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
March 2005, Nihon rinsho. Japanese journal of clinical medicine,
Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
June 2000, Journal of human hypertension,
Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
July 2000, Circulation,
Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
August 1999, Circulation,
Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
June 1999, Hypertension (Dallas, Tex. : 1979),
Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
November 2003, Pflugers Archiv : European journal of physiology,
Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
September 2021, Journal of pharmacological sciences,
Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
January 1990, Microcirculation, endothelium, and lymphatics,
Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
August 1993, Acta paediatrica Japonica : Overseas edition,
Kanta Kishi, and Denan Jin, and Shinji Takai, and Michiko Muramatsu, and Hiroshi Katayama, and Hiroshi Tamai, and Mizuo Miyazaki
November 1998, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!